Molecular and structural characterization of a novel high-prevalence antigen of the Augustine blood group system.
blood group genomics
equilibrative nucleoside transporter 1
hematology - red cells
immunohematology
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
19
12
2022
received:
11
10
2022
accepted:
27
12
2022
pubmed:
7
2
2023
medline:
23
3
2023
entrez:
6
2
2023
Statut:
ppublish
Résumé
An antibody directed against a high-prevalence red blood cell (RBC) antigen was detected in a 67-year-old female patient of North African ancestry with a history of a single pregnancy and blood transfusion. So far, the specificity of the proband's alloantibody remained unknown in our immunohematology reference laboratory. Whole-exome sequencing (WES) was performed on the proband's DNA. The reactivity to the SLC29A1-encoded ENT1 adenosine transporter was investigated by flow cytometry analyses of ENT1-expressing HEK293 cells, and RBCs from Augustine-typed individuals. Erythrocyte protein expression level, nucleoside-binding capacity, and molecular structure of the proband's ENT1 variant were further explored by western blot, flow cytometry, and molecular dynamics calculations, respectively. A missense variant was identified in the SLC29A1 gene, which encodes the Augustine blood group system. It arises from homozygosity for a rare c.242A > G missense mutation that results in a nonsynonymous p.Asn81Ser substitution within the large extracellular loop of ENT1. Flow cytometry analyses demonstrated that the proband's antibody was reactive against HEK-293 cells transfected with control but not proband's SLC29A1 cDNA. Consistent with this finding, proband's antibody was found to be reactive with At(a-) (AUG:-2), but not AUG:-1 (null phenotype) RBCs. Data from structural analysis further supported that the proband's p.Asn81Ser variation does not alter ENT1 binding of its specific inhibitor NBMPR. Our study provides evidence for a novel high-prevalence antigen, AUG4 (also called ATAM after the proband's name) in the Augustine blood group system, encoded by the rare SLC29A1 variant allele AUG*04 (c.242A > G, p.Asn81Ser).
Sections du résumé
BACKGROUND
An antibody directed against a high-prevalence red blood cell (RBC) antigen was detected in a 67-year-old female patient of North African ancestry with a history of a single pregnancy and blood transfusion. So far, the specificity of the proband's alloantibody remained unknown in our immunohematology reference laboratory.
STUDY DESIGN AND METHODS
Whole-exome sequencing (WES) was performed on the proband's DNA. The reactivity to the SLC29A1-encoded ENT1 adenosine transporter was investigated by flow cytometry analyses of ENT1-expressing HEK293 cells, and RBCs from Augustine-typed individuals. Erythrocyte protein expression level, nucleoside-binding capacity, and molecular structure of the proband's ENT1 variant were further explored by western blot, flow cytometry, and molecular dynamics calculations, respectively.
RESULTS
A missense variant was identified in the SLC29A1 gene, which encodes the Augustine blood group system. It arises from homozygosity for a rare c.242A > G missense mutation that results in a nonsynonymous p.Asn81Ser substitution within the large extracellular loop of ENT1. Flow cytometry analyses demonstrated that the proband's antibody was reactive against HEK-293 cells transfected with control but not proband's SLC29A1 cDNA. Consistent with this finding, proband's antibody was found to be reactive with At(a-) (AUG:-2), but not AUG:-1 (null phenotype) RBCs. Data from structural analysis further supported that the proband's p.Asn81Ser variation does not alter ENT1 binding of its specific inhibitor NBMPR.
CONCLUSION
Our study provides evidence for a novel high-prevalence antigen, AUG4 (also called ATAM after the proband's name) in the Augustine blood group system, encoded by the rare SLC29A1 variant allele AUG*04 (c.242A > G, p.Asn81Ser).
Substances chimiques
Blood Group Antigens
0
Isoantibodies
0
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
610-618Informations de copyright
© 2023 AABB.
Références
Daniels G, Ballif BA, Helias V, Saison C, Grimsley S, Mannessier L, et al. Lack of the nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization. Blood. 2015;125:3651-4.
Ramsey G, Sherman LA, Zimmer AM, Spies WG, Sharma L, Arndt P, et al. Clinical significance of anti-At(a). Vox Sang. 1995;69:135-7.
Cash KL, Brown T, Sausais L, Uehlinger J, Reed LJ. Severe delayed hemolytic transfusion reaction secondary to anti-At(a). Transfusion. 1999;39:834-7.
Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion. 2004;44:1273-81.
Sweeney JD, Holme S, McCall L, Huett D, Storry J, Reid M. At(a-) phenotype: description of a family and reduced survival of At(a+) red cells in a proposita with anti-Ata. Transfusion. 1995;35:63-7.
Daniels G. The Augustine blood group system, 48 years in the making. Immunohematology. 2016;32:100-3.
Millard GM, McGowan EC, Wilson B, Martin JR, Spooner M, Morris S, et al. A proposed new low-frequency antigen in the Augustine blood group system associated with a severe case of hemolytic disease of the fetus and newborn. Transfusion. 2018;58:1320-2.
Mikdar M, Gonzalez-Menendez P, Cai X, Zhang Y, Serra M, Dembele AK, et al. The equilibrative nucleoside transporter ENT1 is critical for nucleotide homeostasis and optimal erythropoiesis. Blood. 2021;137:3548-62.
Choi JS, Berdis AJ. Nucleoside transporters: biological insights and therapeutic applications. Future Med Chem. 2012;4:1461-78.
Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, et al. Emerging transporters of clinical importance: an update from the international transporter consortium. Clin Pharmacol Ther. 2013;94:52-63.
Boswell-Casteel RC, Hays FA. Equilibrative nucleoside transporters-a review. Nucleosides Nucleotides Nucleic Acids. 2017;36:7-30.
Nance SJ, Arndt P, Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay. Transfusion. 1987;27:449-52.
Azouzi S, Collec E, Mohandas N, An X, Colin Y, Le Van KC. The human Kell blood group binds the erythroid 4.1R protein: new insights into the 4.1R-dependent red cell membrane complex. Br J Haematol. 2015;171:862-71.
Wright NJ, Lee SY. Structures of human ENT1 in complex with adenosine reuptake inhibitors. Nat Struct Mol Biol. 2019;26:599-606.
Chen Y, Lu H, Zhang N, Zhu Z, Wang S, Li M. PremPS: predicting the impact of missense mutations on protein stability. PLoS Comput Biol. 2020;16:e1008543.
Vander Meersche Y, Cretin G, de Brevern AG, Gelly JC, Galochkina T. MEDUSA: prediction of protein flexibility from sequence. J Mol Biol. 2021;433:166882.
Conkar D, Bayraktar H, Firat-Karalar EN. Centrosomal and ciliary targeting of CCDC66 requires cooperative action of centriolar satellites, microtubules and molecular motors. Sci Rep. 2019;9:14250.
Dabovic B, Chen Y, Colarossi C, Obata H, Zambuto L, Perle MA, et al. Bone abnormalities in latent TGF-[beta] binding protein (Ltbp)-3-null mice indicate a role for Ltbp-3 in modulating TGF-[beta] bioavailability. J Cell Biol. 2002;156:227-32.
Storry JR, Clausen FB, Castilho L, Chen Q, Daniels G, Denomme G, et al. International Society of Blood Transfusion Working Party on red cell Immunogenetics and blood group terminology: report of the Dubai, Copenhagen and Toronto Meetings. Vox Sang. 2019;114:95-102.
Robins MJ, Peng Y, Damaraju VL, Mowles D, Barron G, Tackaberry T, et al. Improved syntheses of 5'-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5′-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor efficacy of gemcitabine. J Med Chem. 2010;53:6040-53.
Lane WJ, Westhoff CM, Uy JM, Aguad M, Smeland-Wagman R, Kaufman RM, et al. Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. Transfusion. 2016;56:743-54.
Osato DH, Huang CC, Kawamoto M, Johns SJ, Stryke D, Wang J, et al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics. 2003;13:297-301.
Verkhivker GM, Agajanian S, Oztas DY, Gupta G. Comparative perturbation-based modeling of the SARS-CoV-2 spike protein binding with host receptor and neutralizing antibodies: structurally adaptable allosteric communication hotspots define spike sites targeted by global circulating mutations. Biochemistry. 2021;60:1459-84.
Fukunaga A, Tsumoto K. Improving the affinity of an antibody for its antigen via long-range electrostatic interactions. Protein Eng Des Sel. 2013;26:773-80.